Sözüer D T, Emre S, Tanman F, Sirin A, Nayir A, Uysal V
Department of Pediatrics, Faculty of Medicine, University of Istanbul, Turkey.
Acta Paediatr Jpn. 1994 Dec;36(6):658-61. doi: 10.1111/j.1442-200x.1994.tb03264.x.
We studied the efficacy of captopril, an angiotensin-converting enzyme inhibitor in treating persistent moderate or severe proteinuria in children with various glomerular diseases other than minimal-change nephrotic syndrome. Captopril was administered for 3 months to 15 normotensive and nonazotemic or mildly azotemic patients (12 boys, 3 girls) in whom corticosteroid and cytotoxic treatment had failed to induce remission. Urinary protein excretion decreased from 2873.14 +/- 1937.50 (mean +/- s.e.m.) to 1684.71 +/- 1463.13 mg/day (P < 0.05). The reduction in proteinuria was not related to a significant fall in systemic blood pressure or a change in renal function. Serum albumin did not rise and side effects due to captopril were not observed. We concluded that, in the short term, captopril can be used safely and effectively for decreasing the proteinuria of nephrotic children unresponsive to conventional therapy.
我们研究了血管紧张素转换酶抑制剂卡托普利对除微小病变型肾病综合征以外的各种肾小球疾病患儿持续性中度或重度蛋白尿的治疗效果。对15名血压正常、无氮质血症或轻度氮质血症的患者（12名男孩，3名女孩）给予卡托普利治疗3个月，这些患者的皮质类固醇和细胞毒性治疗未能诱导缓解。尿蛋白排泄量从2873.14±1937.50（均值±标准误）降至1684.71±1463.13mg/天（P<0.05）。蛋白尿的减少与全身血压的显著下降或肾功能的变化无关。血清白蛋白未升高，未观察到卡托普利引起的副作用。我们得出结论，短期内，卡托普利可安全有效地用于降低对传统治疗无反应的肾病患儿的蛋白尿。
